Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ('Innate' or the 'Company') today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.

The following posters will be presented: IPH5201 as monotherapy or in combination with durvalumab in advanced solid tumors (AstraZeneca)

Abstract Number: 472

Session Name: Poster Display 188P

Session Time: 8 December, 12:30-13:15

Location: Palexpo exhibition centre - Foyer ABC

Presenter: Dr. Martina Imbimbo, Head of Clinic for the Immuno-oncology Department within the Department of Oncology at UNIL CHUV (Lausanne, Switzerland)

Combination of IPH5201, a block antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale

Abstract Number: 384

Session Name: Poster Display 190P

Session Time: 8 December, 12:30-13:15

Location: Palexpo exhibition centre - Foyer ABC

Presenter: Carine Paturel, Senior Director, Research and Drug Development, Products Portfolio Strategy, Innate Pharma (Marseille, France)

A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES) (Institut Paoli-Calmettes)

Abstract Number: 290

Session Name: Poster Display 199TiP

Session Time: 8 December, 12:30-13:15

Location: Palexpo exhibition centre - Foyer ABC

Presenter: Dr. Anthony Goncalves, Professor of Medical Oncology, Institut Paoli-Calmettes (Marseille, France)

The posters will be available on the Publications section of Innate's website following the meeting.

About IPH5201

IPH5201 is a CD39-blocking monoclonal antibody that may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment. It is being developed in partnership with AstraZeneca.

A first-in-human, multi-centre, non-randomised, open-label, phase 1 study (NCT04261075) sponsored by AstraZeneca assessed the safety, efficacy, pharmacokinetics and pharmacodynamics of IPH5201 as monotherapy and in combination with durvalumab in patients with advanced solid tumors.

A Phase 2 clinical trial conducted by Innate in lung cancer is in planning.

About IPH5301

IPH5301 is a CD73-blocking monoclonal antibody currently in an investigator-sponsored Phase 1 trial in collaboration with the Institut Paoli-Calmettes (IPC) and Oncodistinct Network.

By targeting the adenosine immunosuppressive pathway, IPH5301 has the potential to promote anti-tumor immune responses across a wide range of tumors.

Contact:

Tel: +33 (0)4 30 30 30 30

(C) 2022 Electronic News Publishing, source ENP Newswire